Natural History of Paclitaxel-associated Acute Pain Syndrome: A Case Report of Rare Side Effect of Paclitaxel
DOI:
https://doi.org/10.3889/oamjms.2021.7031Keywords:
Chemotherapy-induced neuropathic pain, Acute pain syndrome, Paclitaxel, Carboplatin, Ovarian cancerAbstract
BACKGROUND: One of the harshest side effects following anticancer agent treatments is chemotherapy-induced neuropathic pain. After surgical staging, chemotherapy combination of paclitaxel carboplatin could be a choice of therapy for Stage II or more advanced stage of ovarian cancer. Different side effects may appear after the application of paclitaxel.
CASE REPORT: Here, we show an uncommon case of paclitaxel-acute pain syndrome (P-APS), and how we deal with such cases according to our experiences. One uncommon side effect is P-APS, which can be treated effectively with the administration of non-steroidal anti-inflammatory drugs, corticosteroid, and supportive therapy.
CONCLUSION: One uncommon side effect of Paclitaxel induced neuropathic can be treated effectively with the administration of non-steroidal anti inflammatory drugs, corticosteroid, and supportive therapy.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Society AC. Key Statistics for Ovarian Cancer Atlanta: Leo and Gloria Rosen Family; 2021. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html [Last accessed on 2021 Feb 25].
Institute NC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovarian Cancer; 2021. Available from: https://seer.cancer.gov/statfacts/html/ovary.html [Last accessed on 2021Feb 25].
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376-88. https://doi.org/10.1016/s0140-6736(13)62146-7 PMıd:24767708
Slatnik CL, Duff E. Ovarian cancer: Ensuring early diagnosis. Nurse Pract. 2015;40(9):47-54. https://doi.org/10.1097/01.npr.0000450742.00077.a2 PMıd:26274886
Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European society of gynaecological oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer. 2017;27(7):1534-42. https://doi.org/10.1097/igc.0000000000001041 PMıd:30814245
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN guidelines ınsights: Ovarian cancer, version 1.2019: Featured updates to the NCCN guidelines. J Natl Comp Cancer Network. 2019;17(8):896-909. https://doi.org/10.6004/jnccn.2019.0039 PMıd:31390583
Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Exp Neurol. 2017;288:153-66. https://doi.org/10.1016/j.expneurol.2016.11.015 PMıd:27894788
Da Costa R, Passos GF, Quintão NL, Fernandes ES, Maia JR, Campos MM, et al. Taxane‐induced neurotoxicity: Pathophysiology and therapeutic perspectives. Br J Pharmacol. 2020;177(14):3127-46. https://doi.org/10.1111/bph.15086 PMıd:32352155
Rowinsky E, Eisenhauer E, Chaudhry V, Arbuck S, Donehower RC, editors. Clinical Toxicities Encountered with Paclitaxel (Taxol). Seminars in Oncology; 1993.
Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, et al. Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park, NY). 2003;17(2):271-7; discussion 81. PMıd:12632867
Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171-8. https://doi.org/10.1002/cncr.27489 PMıd:22415454
Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472-8. https://doi.org/10.1200/jco.2010.33.0308 PMıd:21383290
Quintão NL, Santin JR, Stoeberl LC, Corrêa TP, Melato J, Costa R. Pharmacological treatment of chemotherapyınduced neuropathic pain: PPARγ agonists as a promising tool. Front Neurosci. 2019;13:907. https://doi.org/10.3389/fnins.2019.00907 PMıd:31555078
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-ınduced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451 PMıd:30909387
Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105-11. PMıd:23794652
Miltenburg N, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treatment Rev. 2014;40(7):872-82. https://doi.org/10.1016/j.ctrv.2014.04.004 PMıd:24830939
Licht T, Keilani M, Crevenna R. Chemotherapy-induced peripheral neuropathy (CIPN). Memo 2021;14:1-5. https://doi.org/10.1007/s12254-021-00688-3
Colvin LA. Chemotherapy-induced peripheral neuropathy (CIPN): Where are we now? Pain 2019;160(Suppl 1):S1-10. https://doi.org/10.1097/j.pain.0000000000001540 PMıd:31008843
Xu J, Zhang L, Xie M, Li Y, Huang P, Saunders TL, et al. Role of complement in a rat model of paclitaxel-induced peripheral neuropathy. J Immunol. 2018;200(12):4094-101. https://doi.org/10.4049/jimmunol.1701716 PMıd:29695418
Jimenez-Andrade JM, Peters CM, Mejia NA, Ghilardi JR, Kuskowski MA, Mantyh PW. Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett. 2006;405(1-2):62-7. https://doi.org/10.1016/j.neulet.2006.06.043 PMıd:16854522
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-65. PMıd:15057285
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neurooncology. 2012;14(Suppl 4):iv45-54. https://doi.org/10.1093/neuonc/nos203 PMıd:23095830
Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Frontiers in pharmacology. 2013;4:156. https://doi.org/10.3389/fphar.2013.00156 PMıd:24385965
Salvemini D, Little JW, Doyle T, Neumann WL. Roles of reactive oxygen and nitrogen species in pain. Free Radical Biology and Medicine. 2011;51(5):951-66. https://doi.org/10.1016/j.freeradbiomed.2011.01.026 PMıd:21277369
Moran MM, Xu H, Clapham DE. TRP ion channels in the nervous system. Curr Opin Neurobiol. 2004;14(3):362-9. https://doi.org/10.1016/j.conb.2004.05.003 PMıd:15194117
Wang T, Qin L, Liu B, Liu Y, Wilson B, Eling TE, et al. Role of reactive oxygen species in LPS‐induced production of prostaglandin E2 in microglia. J Neurochem. 2004;88(4):939-47. https://doi.org/10.1046/j.1471-4159.2003.02242.x PMıd:14756815
Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol. 1999;72(1):100-1. https://doi.org/10.1006/gyno.1998.5226 PMıd:9889038
Liu CC, Lu N, Cui Y, Yang T, Zhao ZQ, Xin WJ, et al. Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain. 2010;6:76. https://doi.org/10.1186/1744-8069-6-76 PMıd:21050491
Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I, et al. Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer. 2020;28(1):221-7. https://doi.org/10.1007/s00520-019-04808-y PMıd:31016422
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Siti Salima, Ali Budi Harsono, Aisyah Aisyah, Kemala Mantilidewi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
